APLS - Company ID 0001492422
The table below shows Apellis Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $268.30M | $458.58M | $178.49M | $166.80M | $196.83M | $199.69M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $76.96M | $68.19M | $67.02M | $86.42M | $88.57M | $77.95M |
Apellis Pharmaceuticals, Inc. reported annual revenue of $1.00B for fiscal year 2025. That is up 28.5% from $781.37M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $250.65M (FY 2020) to $1.00B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $124.32M |
| $142.68M |
| $131.14M |
| $129.34M |
| $121.98M |
| $128.08M |
| Operating income | $26.47M | $223.18M | -$33.29M | -$83.33M | -$47.28M | -$29.44M |
| Income tax | $496.00K | $602.00K | $466.00K | $341.00K | $592.00K | $114.00K |
| Net income | $18.66M | $215.72M | -$42.15M | -$92.22M | -$57.45M | -$37.66M |
| EPS (diluted) | $0.15 | $1.67 | -$0.33 | -$0.74 | -$0.46 | -$0.30 |